The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B06 | Other hematological agents | |
| 3 | B06A | Other hematological agents | |
| 4 | B06AC | Drugs used in hereditary angioedema | |
| 5 | B06AC05 |
| Active Ingredient | Description | |
|---|---|---|
| Lanadelumab |
Lanadelumab is a fully human, monoclonal antibody (IgG1/Îș-light chain). Lanadelumab inhibits active plasma kallikrein proteolytic activity. Lanadelumab provides sustained control of plasma kallikrein activity and thereby limits bradykinin generation in patients with HAE. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| TAKHZYRO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
